Navigation Links
FDA Invests $2 Million in Partnerships Through Centers of Excellence in Regulatory Science and Innovation
Date:10/26/2011

SILVER SPRING, Md., Oct. 26, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced the award of $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation (CERSI).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The centers, which will be located at the University of Maryland and Georgetown University, will focus on strengthening science and training needed to modernize and improve the ways drugs and medical devices are reviewed and evaluated, a major focus within the FDA.

In August 2011, the agency released the strategic plan for: "Advancing Regulatory Science at FDA" (http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm).

More recently, the agency announced a related innovation initiative, "Driving Biomedical Innovation: Initiatives for Improving Products for Patients" (http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm274333.htm).

"These partnerships represent a critical, necessary and creative investment - one that will benefit not just FDA and academia, but also American consumers and industry," said FDA Chief Scientist Jesse L. Goodman, M.D., M.P.H. "The Centers of Excellence will create new scientific research, training and staff exchange opportunities for FDA and leading area institutions."

Working closely with FDA scientists, CERSI researchers will assist the FDA in driving innovation in medical product development as well as in advancing laboratory, population, behavioral, and manufacturing sciences. The agency chose to pilot the CERSIs in the Washington, D.C. area, to allow for the greatest possible face-to-face collaboration and training with FDA staff.

"These partnerships will promote faster and better scientific approaches to product development, helping people in need and supporting biotech innovation," Goodman said.

For more information:

Advancing Regulatory Science

http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA   


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Advantage Invests in Workstream Inc.
2. Amcor Invests €6.7 Million in the Extension of its Singen Converting Plant in Germany
3. Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products
4. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
5. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
6. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
7. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
8. The SCOOTER Store Invests in Ethics Training for Future Doctors
9. Foundation Venture Capital Group Invests in Start-Up Company Developing Blood Test to Determine Risk and Diagnose Alzheimers Disease
10. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
11. JumpStart Invests in Checkpoint Surgical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology:
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... to treat wrinkles and deep lines by smoothing and tightening the skin of ... techniques out there to address facial aging with very little downtime, Silhouette Instalift ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Castle Dermatology Institute ... several ways to restore a more youthful appearance to the face. Dr. Peyman Ghasri ... along with a variety of other treatments, to rejuvenate and renew the facial appearance. ...
Breaking Medicine News(10 mins):